EVALUATION OF THE EFFICIENCY OF BISPHOSPHONATES IN THE TREATMENT OF OSTEOPOROSIS IN THE CLIMACTERIC PERIOD

Abstract

Osteoporosis (OP) is a widespread metabolic disease of the skeleton, leading to decreased bone strength and increased risk of fractures. OP is a disease of varying nature that affects all age groups, but is most common in older people. For a long time, doctors did not have serious tools to treat this insidious disease and mainly dealt with its consequences - fractures. We have witnessed the birth of a new group of drugs—bisphosphonates (BPs), which have significantly expanded the capabilities of clinicians in the treatment of OP and a number of other bone diseases, as well as calcium metabolism disorders. Modern medicine is based on a solid evidence base. All drugs recommended for use in clinical practice are subject to long-term, multi-stage clinical studies of effectiveness and safety. Possessing different biological activities, these drugs demonstrated one common property in clinical trials, which allowed them to be recommended for the treatment of OP: reducing the risk of fractures. The purpose of the study is to evaluate the effectiveness of bisphosphonates in the treatment of patients with OP in the climacteric period. From 2020 to 2022, 105 climacteric female patients with a confirmed diagnosis of OP of the knee joint, registered in the arthrological IADC department of the multidisciplinary clinic of the Tashkent Medical Academy (TMA), receiving inpatient treatment in the departments of cardiorheumatology and rheumatology, were involved in this research work. They analyzed the clinical course of the disease and the results of laboratory and instrumental examinations. For prospective analysis, the patients were divided into two groups: Group I consisted of female patients with premenopausal OP. Group II consisted of postmenopausal female patients with OP during menopause. In the obtained results, the clinical and laboratory activity indicators of the disease reliably decreased in a statistically significant manner in the group of patients treated with bisphosphonates compared to traditional treatment. Also, indicators of endothelial dysfunction were improved. In UVD and MRI, degenerative changes in bones and joints showed positive dynamics. In conclusion, in the treatment of OP patients in the climacteric period, the use of bisphosphonates (Zoledronic acid) in addition to traditional treatment reduces the frequency of degenerative changes in the joints by reducing the clinical laboratory activity level of the disease, improving endothelial dysfunction, and improving the quality of life of patients.